Efficacy and safety of interferon alfa-2b in combination with vitamins C and E in treatment and prevention of neonatal congenital pneumonia

Abstract

The article presents the results of analysis of works published over 25 years on the effectiveness and safety of interferon alpha-2b in combination with vitamins C and E for the treatment and prevention of congenital pneumonia. The purpose of the work is to summarize and evaluate the results of studies on the effectiveness and safety of the drug based on interferon alpha-2b in combination with ascorbic acid and alpha-tocopherol acetate in complex therapy and for the prevention of congenital pneumonia. Materials and methods . The analysis of available publications was carried out in accordance with the purpose. Selected studies that present the characteristics of the compared groups that received different therapies, conducted a qualitative analysis of the results and statistical processing of data. Results . We selected four researches out of more than a hundred publications, which provided data on the formation and characteristics of the compared groups, and a detailed analysis of the results obtained using statistical methods was carried. The efficacy and safety of interferon-based alpha-2b in combination with vitamins C and E were studied for the treatment of congenital pneumonia in 3 studies. The drug was evaluated of preventive effect in one study. Conclusions . The addition of a combination drug based on interferon alpha-2b in combination with vitamins C and E (Viferon ® ) leads to a significant reduction in the duration of symptoms, the period of hospitalization, the need for a ventilator, and the duration of isolation of pathogens to the treatment regimen for congenital pneumonia. Interferon therapy provides prevention of complications and repeated episodes of infectious diseases. The use of Viferon ® in pregnant women helps to reduce the risk of congenital pneumonia and improve the health indicators of newborns.